Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Non-interventional study on treAtment of chemotherapy-inDuced neutropenia with LIpefilgRastim (XM22) - NADIR

Next Previous
Trial Profile

Non-interventional study on treAtment of chemotherapy-inDuced neutropenia with LIpefilgRastim (XM22) - NADIR

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 26 Dec 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lipegfilgrastim (Primary)
  • Indications Febrile neutropenia; Neutropenia; Non-small cell lung cancer; Small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms NADIR
  • Sponsors Teva Pharmaceutical Industries

    • Most Recent Events

    • 01 Dec 2022 Results (n=301) assessing Prophylaxis of chemotherapy induced neutropenia with lipegfilgrastim in patients with lung cancer published in the Current Medical Research and Opinion
    • 12 Jan 2021 Results of pooled analysis from studies NADIR and LEOS published in the Oncology Research and Treatment
    • 01 Jan 2021 Results of pooled analysis of two studies (NADIR & LEOS) assessing real-world experience with lipegfilgrastim as a neutropenia prophylaxis in a large cohort of lymphoma patients, published in the Anticancer Research.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top